PDCD1 and hepatocellular carcinoma: Disrupting the PD-1 gene by CRISPR/Cas9 in the Glypican-3-directed CAR-T cell has demonstrated diminished CAR-T cell’s exhaustion and enhanced tumor cell killing in hepatocellular carcinoma [157].